P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847372.57687.d4 |
| _version_ | 1797287896953126912 |
|---|---|
| author | M. Matasar N. L. Bartlett L. H. Sehn S. J. Schuster S. Assouline P. Giri J. Kuruvilla M. Canales S. Dietrich K. Fay M. Ku L. J. Nastoupil M. C. Wei S. Yin I. To D. Turner H. Huang J. Min E. Penuel L. E. Budde |
| author_facet | M. Matasar N. L. Bartlett L. H. Sehn S. J. Schuster S. Assouline P. Giri J. Kuruvilla M. Canales S. Dietrich K. Fay M. Ku L. J. Nastoupil M. C. Wei S. Yin I. To D. Turner H. Huang J. Min E. Penuel L. E. Budde |
| author_sort | M. Matasar |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:28Z |
| format | Article |
| id | doaj.art-51e2a67343e64261aae9d764a03201a1 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:28Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-51e2a67343e64261aae9d764a03201a12024-03-02T03:51:55ZengWileyHemaSphere2572-92412022-06-0161016101710.1097/01.HS9.0000847372.57687.d4202206003-01016P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDYM. Matasar0N. L. Bartlett1L. H. Sehn2S. J. Schuster3S. Assouline4P. Giri5J. Kuruvilla6M. Canales7S. Dietrich8K. Fay9M. Ku10L. J. Nastoupil11M. C. Wei12S. Yin13I. To14D. Turner15H. Huang16J. Min17E. Penuel18L. E. Budde191 Memorial Sloan Kettering Cancer Center, New York, NY2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States of America3 BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada4 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States of America5 Jewish General Hospital, Montreal, QC, Canada6 Royal Adelaide Hospital, Adelaide, Australia7 Princess Margaret Cancer Centre, Toronto, ON, Canada8 Hospital Universitario La Paz, Madrid, Spain9 Universitat Heidelberg, Heidelberg, Germany10 St Vincent’s Hospital and Royal North Shore Hospital, Sydney11 St Vincent’s Hospital, University of Melbourne, Melbourne, Australia12 MD Anderson Cancer Center, Houston, TX13 Genentech, Inc., South San Francisco, CA, United States of America13 Genentech, Inc., South San Francisco, CA, United States of America13 Genentech, Inc., South San Francisco, CA, United States of America13 Genentech, Inc., South San Francisco, CA, United States of America14 Hoffmann-La Roche Ltd, Mississauga, ON, Canada15 Roche Products Ltd, Welwyn Garden City, United Kingdom13 Genentech, Inc., South San Francisco, CA, United States of America16 City of Hope, Duarte, CA, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847372.57687.d4 |
| spellingShingle | M. Matasar N. L. Bartlett L. H. Sehn S. J. Schuster S. Assouline P. Giri J. Kuruvilla M. Canales S. Dietrich K. Fay M. Ku L. J. Nastoupil M. C. Wei S. Yin I. To D. Turner H. Huang J. Min E. Penuel L. E. Budde P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY HemaSphere |
| title | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_full | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_fullStr | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_full_unstemmed | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_short | P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY |
| title_sort | p1126 mosunetuzumab is efficacious and well tolerated in patients aged 65 and ≥65 years with relapsed refractory follicular lymphoma and ≥2 prior therapies subgroup analysis of a pivotal phase ii study |
| url | http://journals.lww.com/10.1097/01.HS9.0000847372.57687.d4 |
| work_keys_str_mv | AT mmatasar p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT nlbartlett p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT lhsehn p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT sjschuster p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT sassouline p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT pgiri p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT jkuruvilla p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT mcanales p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT sdietrich p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT kfay p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT mku p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT ljnastoupil p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT mcwei p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT syin p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT ito p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT dturner p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT hhuang p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT jmin p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT epenuel p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy AT lebudde p1126mosunetuzumabisefficaciousandwelltoleratedinpatientsaged65and65yearswithrelapsedrefractoryfollicularlymphomaand2priortherapiessubgroupanalysisofapivotalphaseiistudy |